Novaccess Global Inc XSNX

Healthcare Biotechnology

NovAccess Global Inc. is a biopharmaceutical company, which develops immunotherapies to treat brain tumor patients in the United States. The Company specializes in research related to utilizing a patient’s own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is designed to utilize the patient’s tumor antigens and immune cells, dendritic cells, in combination with TLR adjuvants to initiate an efficient antitumor immune response. This process includes obtaining the patients' tumor cells after surgery, and precursors cells that are matured into dendritic cells from peripheral blood. Its TLR-AD1 platform technology is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. TLR-AD1 technology has a scope of use and is embodied in various different product lines for different clinical situations.

OTCPK:XSNX - Post by User

Novaccess Global Inc > reposted link...you can see the need of solar power cannibas

<< Previous

Bullboard Posts

Next >>

Comment by LittleFundson Jan 10, 2018 10:40pm

74 Views

Post# 27330392

RE:reposted link...you can see the need of solar power cannibas

Thanks.. I belive we could be at the start of something big here. 1 contract with a MJ company and our foot is in the door. Very excited to see how it goes.. if not for sessions I wouldn't doubt we would have been at 1 cent already.. once this gets some legs again it's gunna fly...

<< Previous

Bullboard Posts

Next >>

Thesis Gold makes high-grade discovery at Ring Zone